Oncoral Pharma Overview

  • Founded
  • 2013
  • Status
  • Acquired/​Merged
  • Employees
  • 3
  • Latest Deal Type
  • M&A

Oncoral Pharma General Information


Developer of a novel proprietary tablet formulation designed to treat cancer. The company's formulations are composed of irinotecan, a widely used chemotherapeutic agent with a documented effect on certain solid tumors, enabling patient to overcome important side-effects of novel tablet formulation.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Primary Office
  • Energivej 42
  • 2750 Ballerup
  • Denmark
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncoral Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 14-Sep-2017 Completed Generating Revenue
2. Grant 07-Oct-2013 Completed Startup
1. Early Stage VC 25-Sep-2013 Completed Startup
To view Oncoral Pharma’s complete valuation and funding history, request access »

Oncoral Pharma Board Members (1)

Name Representing Role Since
Hans Schambye Ph.D Self Board Member 000 0000
To view Oncoral Pharma’s complete board members history, request access »

Oncoral Pharma Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncoral Pharma Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Capnova Venture Capital Minority 000 0000 000000 0
The Danish National Advanced Technology Foundation Limited Partner Minority 000 0000 000000 0
To view Oncoral Pharma’s complete investors history, request access »